Stockreport

FDA Approves First Ever Treatment for Neurofibromatosis

SpringWorks Therapeutics, Inc. - common stock  (SWTX) 
Last springworks therapeutics, inc. - common stock earnings: 3/12 04:30 pm Check Earnings Report
PDF NEW YORK (PRWEB) April 13, 2020 The U.S. Food and Drug Administration (FDA) has approved Koselugo (selumetinib) for use in patients with inoperable plexiform neurofibro [Read more]